

Bacterial supplementation as treatment for the irritable bowel syndrome: a randomised double-blind placebo-controlled study

Submission date 12/09/2003	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
Registration date 12/09/2003	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan <input type="checkbox"/> Results
Last Edited 16/02/2015	Condition category Digestive System	<input type="checkbox"/> Individual participant data <input type="checkbox"/> Record updated in last year

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s)

Scientific

Contact name

Dr S Pathmakanthan

Contact details

GI Medicine
Selly Oak Hospital
Birmingham
United Kingdom
B29 6JD

Additional identifiers

Protocol serial number

N0265122367

Study information

Scientific Title

Bacterial supplementation as treatment for the irritable bowel syndrome: a randomised double-blind placebo-controlled study

Study objectives

To assess the tolerance and efficacy of Synbiotic Cocktail 2000 in symptom reduction in the irritable bowel syndrome.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Not provided at time of registration

Study design

Double-blind randomised placebo-controlled trial

Primary study design

Interventional

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Digestive System: Irritable bowel syndrome (IBS)

Interventions

ASSESSMENT ON ADMISSION INTO TRIAL: History and examination, normal blood tests and a previously normal flexible sigmoidoscopy.

ASSESSMENT DURING STUDY PERIOD: All patients will be randomised to receive either the placebo or Synbiotic cocktail 2000 daily for 8 weeks. Prior to this period, there will be a run in period of 2 weeks where patients will record baseline gastrointestinal symptoms on a weekly basis as well as bowel frequency and consistency on a daily basis. A previously validated patient diary will be used scoring abdominal pain, bloating, number and consistency of stool and level of flatulence completed on a weekly basis. After the 2 week run in period, a study period involving Synbiotic or placebo intake will last for 8 weeks. A final questionnaire would be sent out to all patients 6 months post study period, using the same format. Prior to commencement and directly after treatment or placebo period, patients will undergo a hydrogen breath test to ensure bacterial supplementation has not resulted in bacterial overgrowth.

REMOVAL FROM STUDY: Patients may be removed from the study if one or more of the following occurs: Protocol violation or non-compliance on part of the patient, refusal of the patient to continue treatment and a decision by the investigator that termination is in the patient's best medical interest (or a significant unrelated medical illness or complication).

Intervention Type

Drug

Phase

Not Specified

Drug/device/biological/vaccine name(s)

Synbiotic Cocktail 2000

Primary outcome(s)

Not provided at time of registration

Key secondary outcome(s)

Not provided at time of registration

Completion date

13/04/2008

Eligibility

Key inclusion criteria

1. Any patient seen in gastroenterology outpatient clinics at University Hospital Birmingham who fulfils the Rome criteria II for IBS would be offered entry into the trial
2. Patients without a history of malabsorption, previous abdominal surgery, diverticulitis or other organic intestinal disease

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

All

Sex

All

Key exclusion criteria

1. Pregnancy
2. Any form of mental disorder
3. Severe systemic illness

Date of first enrolment

13/04/2003

Date of final enrolment

13/04/2008

Locations

Countries of recruitment

United Kingdom

England

Study participating centre

GI Medicine
Birmingham
United Kingdom
B29 6JD

Sponsor information

Organisation
Department of Health (UK)

Funder(s)

Funder type
Government

Funder Name
University Hospital Birmingham NHS Trust (UK)

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary
Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Participant information sheet	Participant information sheet	11/11/2025	11/11/2025	No	Yes